Nuvectis Pharma Files 2024 10-K, Details Financials

Ticker: NVCT · Form: 10-K · Filed: Feb 25, 2025 · CIK: 1875558

Nuvectis Pharma, Inc. 10-K Filing Summary
FieldDetail
CompanyNuvectis Pharma, Inc. (NVCT)
Form Type10-K
Filed DateFeb 25, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-K, financials, pharmaceutical

Related Tickers: NVCT

TL;DR

NVCT filed 2024 10-K. Financials look stable, check details.

AI Summary

Nuvectis Pharma, Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its operations and financial condition. The company's business address is 1 Bridge Plaza, Suite 275, Fort Lee, NJ 07024, with a phone number of 360-837-7232. The filing details financial data including common stock, retained earnings, and additional paid-in capital for the years 2022, 2023, and 2024.

Why It Matters

This 10-K filing provides investors and stakeholders with a comprehensive overview of Nuvectis Pharma's financial health and operational status for the past fiscal year, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Nuvectis Pharma is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

  • 19495683 — Total Assets (Reported for the fiscal year ending 12/31/2024)
  • 17418886 — Total Liabilities (Reported for the fiscal year ending 12/31/2024)
  • 130000 — Common Stock (Reported for the fiscal year ending 12/31/2024)

Key Players & Entities

  • Nuvectis Pharma, Inc. (company) — Filer of the 10-K
  • 2024-12-31 (date) — Fiscal year end
  • 1 Bridge Plaza, Suite 275, Fort Lee, NJ 07024 (address) — Company business and mailing address
  • 360-837-7232 (phone_number) — Company business phone
  • 2025-02-25 (date) — Filing date

FAQ

What were Nuvectis Pharma's total assets and liabilities as of December 31, 2024?

As of December 31, 2024, Nuvectis Pharma reported total assets of $19,495,683 and total liabilities of $17,418,886.

When was the 10-K filing submitted to the SEC?

The 10-K filing was submitted to the SEC on February 25, 2025.

What is Nuvectis Pharma's primary business classification?

Nuvectis Pharma, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).

What is the company's state of incorporation?

Nuvectis Pharma, Inc. is incorporated in Delaware (DE).

Are there any disclosed subsequent events mentioned in the filing?

Yes, the filing mentions subsequent events related to an 'AtMarketAgreementMember' dated February 21, 2025, and an 'UnderwriterAgreement'.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 25, 2025 regarding Nuvectis Pharma, Inc. (NVCT).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.